To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

Microsoft co-founder Bill Gates reflects on his father's Alzheimer's battle and expresses optimism about advancements in ...

And other biotech news brought to you by The Readout.

A newly approved Alzheimer’s drug is set to be administered for the first time in Taiwan on Monday, Far Eastern Memorial Hospital in New Taipei City announced yesterday. Kisunla, the brand name of the ...

Within the next decade, routine screening and preventive care for Alzheimer's disease could become a reality, say researchers ...

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

Leqembi (lecanemab-irmb) has potential interactions with other medications. These interactions could cause harmful effects. An interaction can occur because one substance causes another substance ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...